From pumps to prevention: recent advances in the treatment of type 1 diabetes

Drug Discovery Today

Volumn 14, Issue 19-20, 2009, Pages 973-981

  Sherr, Jennifer ^a   Cengiz, Eda ^a   Tamborlane, William V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABATACEPT; ANTIDIABETIC AGENT; CD3 ANTIBODY; COLECALCIFEROL; DOCOSAHEXAENOIC ACID; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 AGONIST; HEMOGLOBIN A1C; IMMUNOMODULATING AGENT; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; INTERLEUKIN 2; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; NICOTINAMIDE; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; RAPAMYCIN; ROSIGLITAZONE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEMORRHAGIC PANCREATITIS; ARTIFICIAL PANCREAS; AUTOIMMUNITY; BLOOD GLUCOSE MONITORING; BODY MASS; BOLUS INJECTION; CELL DESTRUCTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMORRHAGIC PANCREATITIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RESISTANCE; LOW DRUG DOSE; NAUSEA; PANCREAS ISLET BETA CELL; REVIEW; SIDE EFFECT; VOMITING; WEIGHT GAIN;

ANIMALS; AUTOIMMUNITY; BIOSENSING TECHNIQUES; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC FACTORS; INFUSION PUMPS; INSULIN; INSULIN-SECRETING CELLS; PANCREAS, ARTIFICIAL; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 70349337001     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.06.011     Document Type: Review

References (88)

1. Tamborlane W.V., et al. Reduction to normal of plasma glucose in juvenile diabetics by subcutaneous administration of insulin with a portable infusion pump. N. Engl. J. Med. 300 (1979) 573-578
2. Pickup J.C., et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. Br. Med. J. 1 (1978) 204-207
3. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. The Diabetes Control and Complications Trial. N. Engl. J. Med. 329 (1993) 977-986
4. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. J. Pediatr. 125 (1994) 177-188
5. Boland E.A., et al. Continuous subcutaneous insulin infusion: a new way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type 1 diabetes. Diabetes Care 22 (1999) 1779-1784
6. Ahern J.A., et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 3 (2002) 10-15
7. Maniatis A.K., et al. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 107 (2001) 351-356
8. Sulli N., and Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. J. Pediatr. Endocrinol. 16 (2003) 393-399
9. Plotnick L.P., et al. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 26 (2003) 1142-1146
10. Willi S.M., et al. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes mellitus. J. Pediatr. 143 (2003) 796-801
11. Alemzadeh R., et al. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. J. Pediatr. 114 (2004) e91-e95
12. Weinzimer S.A., et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. J. Pediatr. 114 (2004) 1601-1604
13. Mack-Fogg J.E., et al. Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective. Pediatric Diabetes 6 (2005) 17-21
14. Schiaffini R., et al. An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. Diabetes Metab. Res. Rev. 21 (2005) 347-352
15. Jeha G.S., et al. Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decrease glucose excursions and the risk of hypoglycemia. Diabetes Technol. Ther. 7 (2005) 876-884
16. Nimri R., et al. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. J. Pediatr. 117 (2006) 2126-2131
17. Berhe T., et al. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study. J. Pediatr. 117 (2006) 2132-2137
18. Sulli N., and Shashaj B. Long-term benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes: a 4-year follow-up. Diabet Med 23 (2006) 900-906
19. Scrimgeour L., et al. Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes. Diabetes Technol. Ther. 9 (2007) 421-428
20. Jakisch B., et al., on behalf of the German/Austrian DV Iniative, the Working Group for Paediatric Pump Therapy. Comparison of continuous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicenter matched-pair cohort analysis over 3 years. Diabetic Med. 25 (2008) 80-85
21. Litton J., et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes. J. Pediatr. 141 (2002) 490-495
22. Hanas R., and Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. Pediatric Diabetes 7 (2006) 25-31
23. DeVries J., et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 25 (2002) 2074-2080
24. Weintrob N., et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 112 (2003) 559-564
25. Hoogma R., et al., on behalf of the 5-Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5 nations trial. Diabetes Med. 23 (2006) 141-147
26. DiMeglio L., et al. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J. Pediatr. 145 (2004) 380-384
27. Wilson D., et al. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 28 (2005) 15-19
28. Fox L., et al. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 28 (2005) 1277-1281
29. Opipari-Arrigan L., et al. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatric Diabetes 8 (2007) 377-383
30. Doyle E., et al. A randomized, prospective trail comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 27 (2004) 1554-1558
31. Schiaffini R., et al. Basal insulin supplementation in Type 1 diabetic children: a long term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin. J. Endocrinol. Invest. 30 (2007) 572-577
32. Pankowska E., et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatric Diabetes 10 (2009) 52-58
33. Shashaj B., et al. Benefits of bolus calculator in pre- and postprandial glycemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabetic Med. 25 (2008) 1036-1042
34. Pankowska E., et al. Memory of insulin pumps and their record as a source of information about insulin therapy in children and adolescents with type 1 diabetes. Diabetes Technol. Ther. 7 (2005) 308-314
35. Burdick J., et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 113 (2004) e221-e224
36. Eugster E., Francis G., the Lawson-Wilkins Drug, and Therapeutics Committee. Position statement: continuous subcutaneous insulin infusion in very young children with type 1 diabetes. Pediatrics 118 (2006) e1244-e1249
37. Phillip M., et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 30 (2007) 1653-1662
38. Amiel S.A., et al. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J. Clin. Endocrinol. Metab. 72 (1991) 277-282
39. Mohn A., et al. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Diabetes Care 22 1 (1999) 27-32
40. Swan K.L., et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with TIDM. Diabetes Care 31 (2008) 44-46
41. Heise T., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 6 (2004) 1614-1620
42. Swan K.L., et al. To mix or not to mix? A preliminary report on the effect of mixing on the pharmacodynamics of insulin aspart and detemir. Diabetes 57 Suppl 1 (2008) A503
43. Chase P., et al. Insulin glargine vs. intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes. J. Pediatr. 153 (2008) 547-553
44. Nyholm B., et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48 (1999) 935-941
45. Edelman S., et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29 (2006) 2189-2195
46. Whitehouse F., et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25 (2002) 724-730
47. Ratner R.E., et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 21 (2004) 1204-1212
48. Whitehouse F., et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlinitide as and adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25 (2002) 724-730
49. Hamilton J., et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 26 (2003) 138-143
50. Sarnblad S., et al. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomized placebo-controlled trial with aspects on insulin sensitivity. Eur. J. Endocrinol. 149 (2003) 323-329
51. Khan A.S., et al. The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. Diabet Med. 23 (2006) 1079-1084
52. Strowig S.M., and Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 28 (2005) 1562-1567
53. Zdravkovic V., et al. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J. Pediatr. 149 (2006) 845-849
54. Grey A., et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92 (2007) 1305-1310
55. Schwartz A.V., et al. Thiazolidinedione use and bone loss in older diabetic adults. J. Clin. Endocrinol. Metab. 91 (2006) 3349-3354
56. Yaturu S., et al. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30 (2007) 1574-1576
57. Dupre J., et al. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 3469-3473
58. FDA Alert Information for Healthcare Professionals in October 2007. (www.fda.gov).
59. Behme M.T., et al. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr. Disord. 3 (2003) 3
60. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 17 (2003) 161-171
61. Boland E., et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 24 (2001) 1858-1862
62. The Diabetes Research in Children Network Study Group. A randomized multicenter trial comparing the GlucoWatch biographer with standard glucose monitoring in children with type 1 diabetes. Diabetes Care 28 (2005) 1101-1106
63. Sachedina N., and Pickup J. Performance assessment of the Medtronic-Minimed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabetes Med. 20 (2003) 1012-1015
64. Mastrototaro J., et al. The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol. Ther. 10 (2008) 385-390
65. The Diabetes Research in Children Network Study Group. Accuracy of the modified continuous glucose monitoring system sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) Study. Diabetes Technol. Ther. 7 (2005) 109-114
66. Wilson D., et al., the DirecNet Study Group. The accuracy of the freestyle navigator continuous glucose monitoring system in children with type 1 diabetes. Diabetes Care 30 (2007) 59-64
67. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N. Engl. J. Med. 359 (2008) 1-13
68. Panteleon A., et al. Evaluation of the effect of gain on meal response of an automated closed-loop insulin delivery system. Diabetes 55 (2006) 1995-2000
69. Weinzimer S., et al. Fully automated closed loop insulin delivery vs. semi-automated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31 (2008) 934-939
70. Atkinson M.A. ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease?. Diabetes 54 (2005) 1253-1263
71. Eisenbarth G.S. Type 1 diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314 (1986) 1360-1380
72. Krischer J.P., et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J. Clin. Endocrinol. Metab. 88 (2003) 103-108
73. Achenbach P., et al. Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia 49 (2006) 2969-2976
74. Gale E.A., et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet 363 (2004) 925-931
75. Gale E.A. Intervening before the onset of Type 1 Diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetologia 46 (2003) 339-346
76. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1685-1691
77. Skyler J., et al. Effects of oral insulin in relative of patients with type 1 diabetes. The Diabetes Prevention Trial-Type 1. Diabetes Care 28 (2005) 1068-1076
78. Nanto-Salonen K., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double blind, randomized controlled trial. Lancet 372 (2008) 1746-1755
79. Bougneres P.F., et al. Factors associated with early remission of type 1 diabetes in children treated with cyclosporine. N. Engl. J. Med. 318 (1988) 663-670
80. Silverstein J., et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 319 (1988) 599-604
81. Herold K.C., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1692-1698
82. Keymeulen B., et al. Insulin needs after CD-3 therapy in new onset type 1 diabetes. N. Engl. J. Med. 352 (2005) 2598-2608
83. Herold K.C., et al. A single course of anti-CD3 monoclonal antibody hOKT3 (gamma)1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769
84. Lehmann P.V., et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358 (1992) 155-157
85. Ludvigsson J., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359 (2008) 1909-1920
86. Bresson D., et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116 (2006) 1371-1381
87. Sherry N., et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 mAB by enhancing recovery of beta cells. Endocrinology 148 (2007) 5136-5144
88. Hadjiyanni I., et al. Exendin-4 modulates diabetes onset in non obese diabetic mice. Endocrinology 149 (2008) 1338-1349